ckd glp 1 Real-World Evidence for GLP-1 Receptor Agonists Across the Spectrum – AJKD Blog SGLT2 vs GLP-1 for CKD:

Dunbar JC, Hu Y, Lu H

(PubMed) Petersen JM, Parker SE, Crider KS, Tinker SC, Mitchell AA, Werler MM

Market Segmentation Overview By product type , the GLP-1 receptor agonists segment led the GLP-1 market with an 86% share in 2025, due to the continued adoption of diabetes management and weight loss

They slow gastric emptying, stimulate insulin release, and reduce hunger signals at the brain level

That said, the AACE consensus statement (2025) already suggests that tirzepatide could replicate semaglutides kidney benefits, lending support to the view that CKD impact may reflect a class effect, rather than a single-agent effect